This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Sanofi Appoints Belén Garijo CEO
Business leadership change

Sanofi Appoints Belén Garijo CEO

Analysis based on 7 articles · First reported Apr 29, 2026 · Last updated Apr 29, 2026

Sentiment
20
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The appointment of Belén Garijo as CEO of Sanofi is expected to bring a new phase of development, focusing on execution discipline and capital allocation, which could positively impact Sanofi's stock performance. The approval of the 2025 accounts and dividend distribution provides clarity and confidence to shareholders.

Pharmaceuticals Biotechnology Telecommunications
Event Summary

Sanofi's Mixed General Meeting of Shareholders on April 29, 2026, approved all resolutions, most notably the appointment of Belén Garijo as Director and Chief Executive Officer, effective May 1, 2026. Frédéric Oudéa, Chairman of the Board, highlighted Garijo's scientific expertise and operational leadership, emphasizing her role in strengthening execution and refining capital allocation for Sanofi. The meeting also approved the social and consolidated accounts for fiscal year 2025 and declared an annual dividend of €4.12 per share, payable on May 7, 2026. Additionally, board mandates for Christophe Babule and Jean-Paul Kress were renewed, and Christel Heydemann, CEO of Orange Group, was welcomed as an independent board member. Following the departures of Paul Hudson and Patrick Kron, Frédéric Oudéa was appointed Chairman of the Appointments, Governance and CSR Committee, with Belén Garijo joining the Strategic Committee and Christel Heydemann joining the Appointments, Governance and CSR Committee and the Compensation Committee.

Entities Involved
per
Christel Heydemann
Christel Heydemann, CEO of Orange Group, joined Sanofi's Board of Directors as an independent member, contributing her knowledge in Digital and AI.
Importance 30.0 Sentiment 10.0
subs
Sanofi — Genzyme
Belén Garijo previously led the integration of Sanofi — Genzyme following its acquisition by Sanofi-Aventis.
Importance 5.0 Sentiment 0.0
per
Paul Hudson
Paul Hudson departed from Sanofi, leading to changes in committee appointments.
Importance 5.0 Sentiment 0.0
per
Patrick Kron
Patrick Kron departed from Sanofi, leading to changes in committee appointments.
Importance 5.0 Sentiment 0.0
per
Christophe Babule
Christophe Babule's board mandate at Sanofi was renewed.
Importance 5.0 Sentiment 0.0
per
Jean-Paul Kress
Jean-Paul Kress's board mandate at Sanofi was renewed.
Importance 5.0 Sentiment 0.0
stock
Orange Group
Importance 0.0 Sentiment 0.0
per
Frédéric Oudéa
Importance 0.0 Sentiment 0.0
stock
Merck Group
Importance 0.0 Sentiment 0.0
stock
Sanofi
Importance 0.0 Sentiment 0.0
per
Belén Garijo
Importance 0 Sentiment 0
Relationships
Christel Heydemann related ↔ Orange Group
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.